文献速递前列腺癌

结合斯德哥尔摩3检测与磁共振成像的前列腺癌统一风险预测模型

A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
PubMed 文献 · Eur Urol Oncol · 2018-10-09

基于532例接受前列腺磁共振成像的前瞻性多中心STHLM3-MRI诊断研究数据,构建结合斯德哥尔摩3评分与非增强磁共振改良PI-RADS评分的统一风险预测模型S3M-MRI。S3M-MRI的AUC为0.88,显著高于斯德哥尔摩3的0.86和改良PI-RADS的0.83,但相较先做斯德哥尔摩3、阳性者再做磁共振的序贯策略仅边际改善,且磁共振检查量增加60%。

要点

  • S3M-MRI的AUC为0.88,显著高于斯德哥尔摩3的0.86和改良PI-RADS的0.83。
  • 先做斯德哥尔摩3、阳性者再做磁共振可避免38%的磁共振检查。
  • S3M-MRI相较序贯策略仅边际改善,但磁共振检查量增加60%。

核心结论

  • 统一S3M-MRI模型优于斯德哥尔摩3模型和单独改良PI-RADS。
  • 但S3M-MRI相较先做斯德哥尔摩3、阳性者再做磁共振的序贯使用仅边际改善,且磁共振检查量增加60%。

研究设计与样本

  • 使用前瞻性多中心STHLM3-MRI诊断研究中532例男性的数据构建S3M-MRI。
  • 比较S3M-MRI与斯德哥尔摩3和改良PI-RADS单独的模型区分度、校准度和净获益。
  • 按三种模型组合的使用方式比较五种诊断策略的临床结局。

主要发现

  • S3M-MRI的AUC为0.88(95%CI 0.85-0.91),显著高于斯德哥尔摩3的0.86(95%CI 0.83-0.89)和改良PI-RADS的0.83(95%CI 0.79-0.87),p=0.04。
  • 在活检推荐的临床相关概率阈值上,S3M-MRI的决策曲线净获益高于斯德哥尔摩3和改良PI-RADS。
  • 先做斯德哥尔摩3、仅对斯德哥尔摩3阳性者做磁共振的序贯策略,不必要活检数为64 vs 69,诊断的ISUP 1级癌为56 vs 51,对ISUP≥2级癌的敏感性相似,同时避免38%的磁共振检查。

局限性

  • 研究人群种族同质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk prediction models and magnetic resonance imaging (MRI) of the prostate can reduce unnecessary biopsies and overdiagnosis of low-risk prostate cancer. However, it is unclear how these tools should be used in concert. OBJECTIVE: To develop a unified risk prediction model (S3M-MRI) that combines the Stockholm3 score (based on protein and genetic markers and clinical variables) and Prostate Imaging-Reporting and Data System v.2 scores modified for MRI without contrast (modPI-RADS). DESIGN, SETTING, AND PARTICIPANTS: We used data for 532 men from the prospective multicentre STHLM3-MRI diagnostic study to construct S3M-MRI. We compared S3M-MRI to Stockholm3 and modPI-RADS alone with respect to model discrimination, calibration, and net benefit. We also compared clinical outcomes for five diagnostic strategies according to the use of combinations of the three models. RESULTS AND LIMITATIONS: The area under the receiver operating characteristic curve (AUC) was 0.88 (95% confidence interval [CI] 0.85-0.91) for S3M-MRI, which was significantly higher (p=0.04) than for Stockholm3 (0.86, 95% CI 0.83-0.89) and modPI-RADS (0.83, 95% CI 0.79-0.87). S3M-MRI had a higher net benefit on decision curve analysis for clinically relevant probability thresholds for biopsy recommendation in comparison to Stockholm3 and modPI-RADS. However, for different diagnostic strategies, sequential use of Stockholm3 followed by MRI only for Stockholm3-positive men resulted in a similar number of unnecessary biopsies (64 vs 69) and diagnosed International Society of Urological Pathology (ISUP) grade group 1 cancers (56 vs 51) at similar sensitivity for ISUP grade group ≥2 cancers, while avoiding 38% of MRI scans. Limitations include the ethnically homogeneous study population. CONCLUSIONS: The unified S3M-MRI model was superior to the Stockholm3 model and modPI-RADS alone. However, the S3M-MRI improvement was marginal compared to sequential use of Stockholm3 followed by MRI, and resulted in 60% more MRI scans. PATIENT SUMMARY: A new risk prediction model combining clinical variables, genetic and protein biomarkers, and results from prostate magnetic resonance imaging improved the clinical outcome performance of prostate cancer diagnostics.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Palsdottir T, Nordström T, Aly M, et al. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. Eur Urol Oncol. 2018. PMID: 31412016. doi:10.1016/j.euo.2018.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。